Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 17-24 |
| Number of pages | 8 |
| Journal | Seminars in Cutaneous Medicine and Surgery |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2012 |
Fingerprint
Keywords
- Atopic dermatitis
- Barrier cream
- Biologics
- Drug
- Eczema
- Medication
- Proactive therapy
- Systemic
- Therapy
- Topical
- Treatment
ASJC Scopus subject areas
- Dermatology
- Surgery
Cite this
Advances in Management of Atopic Dermatitis : New Therapies and Novel Uses of Existing Treatments. / Chase, Elizabeth P.; Armstrong, April W.
In: Seminars in Cutaneous Medicine and Surgery, Vol. 31, No. 1, 03.2012, p. 17-24.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advances in Management of Atopic Dermatitis
T2 - New Therapies and Novel Uses of Existing Treatments
AU - Chase, Elizabeth P.
AU - Armstrong, April W.
PY - 2012/3
Y1 - 2012/3
N2 - Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.
AB - Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.
KW - Atopic dermatitis
KW - Barrier cream
KW - Biologics
KW - Drug
KW - Eczema
KW - Medication
KW - Proactive therapy
KW - Systemic
KW - Therapy
KW - Topical
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84857222418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857222418&partnerID=8YFLogxK
U2 - 10.1016/j.sder.2011.11.005
DO - 10.1016/j.sder.2011.11.005
M3 - Article
C2 - 22361285
AN - SCOPUS:84857222418
VL - 31
SP - 17
EP - 24
JO - Seminars in Cutaneous Medicine and Surgery
JF - Seminars in Cutaneous Medicine and Surgery
SN - 1085-5629
IS - 1
ER -